Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 761-767

  Kanzaki, Masatoshi ^a   Kakinuma, Hideaki ^a   Kumazawa, Teruaki ^a   Inoue, Takamitsu ^a   Saito, Mitsuru ^a   Narita, Shintarou ^a   Yuasa, Takeshi ^a   Tsuchiya, Norihiko ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Depsipeptide; Docetaxel; Gemcitabine; Histone deacetylase inhibitor; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DEPSIPEPTIDE; DOCETAXEL; DRUG DERIVATIVE; FR 901228; GEMCITABINE; HISTONE DEACETYLASE; TAXOID;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; HUMAN; MALE; MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DEPSIPEPTIDES; DRUG SYNERGISM; HISTONE DEACETYLASES; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROSTATIC NEOPLASMS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34249949312     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.761     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
2. Wakai K: Descriptive epidemiology of prostate cancer in Japan and Western countries. Nippon Rinsho 63: 207-212, 2005.
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989. (Pubitemid 19211484)
4. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ and Lowe BA: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036-1042, 1998. (Pubitemid 28457865)
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
7. Armstrong AJ and Carducci MA: Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep 7: 220-227, 2005. (Pubitemid 40674349)
8. Grunstein M: Histone acetylation in chromatin structure and transcription: Nature 389: 349-352, 1997.
9. Turner BM: Decoding the nucleosome. Cell 75: 5-8, 1993.
10. Emiliani S, Fischle W, Van Lint C, Al-Abed Y and Verdin E: Characterization of a human RPD3 ortholog, HDAC3. Proc Natl Acad Sci USA 95: 2795-2800, 1998. (Pubitemid 28135808)
11. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ and Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92: 1300-1304, 2001. (Pubitemid 34036893)
12. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T and Takahashi T: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 112: 26-32, 2004. (Pubitemid 39249488)
13. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S and Iwase H: HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10: 6962-6968, 2004. (Pubitemid 39383047)
14. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE and Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189, 2004. (Pubitemid 38481229)
15. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
16. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006. (Pubitemid 43054973)
17. Marks PA and Dokmanovic M: Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497-1511, 2005. (Pubitemid 41749195)
18. -) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86: 3430-3435, 2001.
19. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, Manda T and Mutoh S: Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 66: 897-906, 2003. (Pubitemid 37083586)
20. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M and Horinouchi S: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921, 2002. (Pubitemid 34984414)
21. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003. (Pubitemid 37413470)
22. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M and Ottmann OG: Clinical trial of valproic acid and all-trans retinoic acid in patients with poorrisk acute myeloid leukemia. Cancer 104: 2717-2725, 2005. (Pubitemid 41798282)
23. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV and Bates SE: P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83: 817-825, 2000.
24. Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE and Sackett DL: FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 11: 445-454, 2000.
25. Zhu WG, Lakshmanan RR, Beal MD and Otterson GA: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327-1333, 2001. (Pubitemid 34292551)
26. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D and Seto E: Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26: 349-353, 2000.
27. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T and Mutoh S: Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 195: 161-168, 2003. (Pubitemid 36588965)
28. Ito T, Ouchida M, Morimoto Y, Yoshida A, Jitsumori Y, Ozaki T, Sonobe H, Inoue H and Shimizu K: Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 224: 311-319, 2005. (Pubitemid 40725851)
29. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK and Grever MR: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967, 2005. (Pubitemid 40170861)
30. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R and Bates SE: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868, 2001.
31. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP and Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728, 2002. (Pubitemid 34742100)